03:21 PM EST - Immunovaccine Inc. : Announced the achievement of several milestones in its ongoing collaboration with global animal health company Zoetis to develop cattle vaccines. In recent controlled studies, the Immunovaccine formulations met efficacy and duration of immunity endpoints against two disease targets. These results will enable Zoetis to advance two Immunovaccine-formulated vaccine candidates into late-stage testing. Immunovaccine Inc.
shares T.IMV are trading down $0.02 at $1.18.
